Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
|Articles|October 27, 2021
Pharmacy Clinical Pearl of the Day: Breast Cancer
Author(s)Saro Arakelians, PharmD
After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Advertisement
Clinical Pearl of the Day: Breast Cancer
Breast cancer is a cancer that forms in the cells of the breasts.
Insight:
- After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
- Breast cancer can occur in both men and women, but it's far more common in women.
- Symptoms include a breast lump or thickening that feels different; change in the size, shape, or appearance of the breast; a newly inverted nipple; peeling, scaling, crusting or flaking of the pigmented area of skin; and redness or pitting of the skin.
- Risk factors include being female, increasing age, history of breast cancer, family history, obesity, and having a child at an older age.
- Diagnostic tools may include breast exam, mammogram, breast ultrasound, biopsy, and MRI.
- Treatment includes lumpectomy, mastectomy, sentinel node biopsy, axillary lymph node dissection, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and palliative care.
- Chemotherapy can be given before surgery (neoadjuvant) or after surgery (adjuvant).
- Adjuvant and neo-adjuvant drug may include anthracyclines, such as doxorubicin (Adriamycin), epirubicin (Ellence); taxanes such as paclitaxel (Taxol) and docetaxel (Taxotere), 5-Fluorouracil (5-FU) or capecitabine, cyclophosphamide (Cytoxan), and carboplatin.
Sources:
Advertisement
Related to this article
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Advertisement
Advertisement